Development

Articles

The manufacture of gene therapy vectors is shifting to more modern technologies.

Modernizing Bioprocessing for Gene Therapy Viral Vectors

Ronald A. Rader is senior director, Technical Research, at BioPlan Associates.

Cellular and gene therapy fields are currently on track for, if not already experiencing, a serious capacity crunch.

Cellular and Gene Therapies Face a Manufacturing Capacity Crunch

The acquisition will support the accelerated commercialization of Kyslecel (autologous pancreatic islets), Koligo’s personalized cell therapy for treating pancreatitis.

Orgenesis to Acquire Koligo Therapeutics

The agreement between the two companies will significantly increase global supply capacity for Lilly's potential COVID-19 treatments.

Lilly and Amgen in Manufacturing Collaboration for COVID-19 Antibody Therapies

The companies have entered into a strategic partnership for the CMC development and manufacturing of Ansun’s biologics pipeline.

HJB and Ansun Biopharma Partner on Biologics CMC Development and Manufacturing

The companies will collaborate on the production of a novel anti-SARS-CoV-2 immunoadhesin in iBio’s FastPharming manufacturing system.

iBio and Planet Biotechnology Partner to Develop COVID-19 Therapeutic

AbCellera’s recent acquisition of the OrthoMab bispecific platform is expected to accelerate antibody product development.

AbCellera’s Acquisition of OrthoMab Bispecific Platform Propels Antibody Development

In the study, GigaGen presents a novel technology for producing a new class of drug, recombinant hyperimmunes, that may potentially generate new COVID-19 therapies.

GigaGen Highlights Research Describing New Class of Drugs for Potential COVID-19 Therapy

Susan Haigney is managing editor of BioPharm International, susan.haigney@ubm.com.

The COVID-19 pandemic has raised several questions about the safety of the pharmaceutical materials supply chain. Is onshoring the answer?

Ensuring a Safe and Robust Supply of Pharma Materials

The early success seen on the market for approved cell and gene therapies poses both technical and manufacturing challenges for pipeline candidates on the road to commercialization.

Biologics APIs